DK0910365T3 - Væksthæmning og udslettelse af faste tumorer ved at anvende en prolactinmodulator og en fotosensibilisator - Google Patents

Væksthæmning og udslettelse af faste tumorer ved at anvende en prolactinmodulator og en fotosensibilisator

Info

Publication number
DK0910365T3
DK0910365T3 DK97922668T DK97922668T DK0910365T3 DK 0910365 T3 DK0910365 T3 DK 0910365T3 DK 97922668 T DK97922668 T DK 97922668T DK 97922668 T DK97922668 T DK 97922668T DK 0910365 T3 DK0910365 T3 DK 0910365T3
Authority
DK
Denmark
Prior art keywords
photosensitizer
prolactin
obliteration
growth inhibition
solid tumors
Prior art date
Application number
DK97922668T
Other languages
English (en)
Inventor
Anthony H Cincotta
Louis Cincotta
Original Assignee
Harvard College
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Gen Hospital Corp filed Critical Harvard College
Application granted granted Critical
Publication of DK0910365T3 publication Critical patent/DK0910365T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK97922668T 1996-05-01 1997-04-15 Væksthæmning og udslettelse af faste tumorer ved at anvende en prolactinmodulator og en fotosensibilisator DK0910365T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1661996P 1996-05-01 1996-05-01
PCT/US1997/007577 WO1997040829A1 (en) 1996-05-01 1997-04-15 Growth inhibition and eradication of solid tumors using neuroendocrine resetting therapy and photodynamic therapy

Publications (1)

Publication Number Publication Date
DK0910365T3 true DK0910365T3 (da) 2003-10-20

Family

ID=21778086

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97922668T DK0910365T3 (da) 1996-05-01 1997-04-15 Væksthæmning og udslettelse af faste tumorer ved at anvende en prolactinmodulator og en fotosensibilisator

Country Status (9)

Country Link
US (2) US20010049350A1 (da)
EP (1) EP0910365B1 (da)
JP (1) JP2000509398A (da)
AT (1) ATE243513T1 (da)
CA (1) CA2253207C (da)
DE (1) DE69723077T2 (da)
DK (1) DK0910365T3 (da)
ES (1) ES2205215T3 (da)
WO (1) WO1997040829A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390668B2 (en) 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
CA2375865C (en) * 1999-06-03 2009-08-18 The General Hospital Corporation Treatment and analysis of proliferative disorders
DE10229456A1 (de) * 2002-07-01 2004-02-05 Wank, Rudolf, Prof. Dr.med. Verwendung von Dopamin-Rezeptor-Agonisten zur Behandlung von Hautgeschwülsten und Warzen
CN101516255A (zh) * 2006-09-13 2009-08-26 皇家飞利浦电子股份有限公司 用于自动调整褪黑素的剂量和/或递送褪黑素的装置
WO2008148015A1 (en) * 2007-05-24 2008-12-04 The Trustees Of Columbia University In The City Of New York Sustained release formulation of melatonin
US9724069B2 (en) * 2009-12-22 2017-08-08 Biolitec Unternehmensbeteiligungs Ii Ag Tissue resection under image guidance/control
EP2531211A4 (en) 2010-02-03 2013-10-23 Orbis Health Solutions Llc METHOD FOR THE SENSITIZATION OF CELLS TO TREATMENT AGAINST CANCER
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
CN120713906A (zh) 2016-04-20 2025-09-30 维罗技术有限责任公司 用于治疗代谢失调的组合物和方法
EP3697418B1 (en) 2017-10-18 2024-07-24 VeroScience LLC Improved bromocriptine formulations
WO2021061818A1 (en) 2019-09-23 2021-04-01 Veroscience Llc Method for inducing tumor regression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5792748A (en) * 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
US6017914A (en) * 1997-09-03 2000-01-25 Eli Lilly And Company Benzo[b]thiophene compounds, intermediates, formulations, and methods

Also Published As

Publication number Publication date
CA2253207C (en) 2008-12-30
DE69723077T2 (de) 2004-05-06
ES2205215T3 (es) 2004-05-01
DE69723077D1 (de) 2003-07-31
EP0910365A1 (en) 1999-04-28
US20010049350A1 (en) 2001-12-06
JP2000509398A (ja) 2000-07-25
ATE243513T1 (de) 2003-07-15
EP0910365B1 (en) 2003-06-25
CA2253207A1 (en) 1997-11-06
WO1997040829A1 (en) 1997-11-06
US20040102383A1 (en) 2004-05-27
EP0910365A4 (en) 1999-12-01

Similar Documents

Publication Publication Date Title
AU732673C (en) Device for the photodynamic treatment of living beings and of the organs thereof
DE69723077D1 (de) Wachstumshemmung und abtoetung solider tumore unter verwendung eines prolaktin-modulators und eines photosensitizers
DK1083899T3 (da) Derivater af 1-dexoy-galactonojirimycin og anvendelse heraf i behandlingen af lysosomale oplagringssygdomme ved øgning af lysosomal alpha-galactosidase A
ATE277515T1 (de) Verfahren zur behandlung von pigmentierten krebszellen durch photodynamische therapie
ES2160173T3 (es) Nuevo derivado de rodamina para la terapia fotodinamica de cancer y purgacion en vitro de leucemia.
NO984163D0 (no) Forbedret syn ved fotodynamisk terapi av öyet
BG102696A (bg) Антипсориазисен лак за нокти
AR022583A1 (es) Secuencias antitumorales anti-sentido dirigidas contra los componentes r1 y r2 de la reductasa de los ribonucleotidos
ATE258486T1 (de) Holzbehandlungsverfahren
Wulf et al. Counteracting side-effects of photodynamic therapy for actinic keratoses
RU94007018A (ru) Способ лечения больных хроническим простатитом
ES2187799T3 (es) Complejos de bis-platino con derivados de polimetileno como ligandos que tienen actividad antitumoral.
ES2192885T3 (es) Metodo para evitar e inhibir la aterosclerosis en los mamiferos.
ATE480571T1 (de) Verwendung von maleimidderivaten in wasserverträglichen energie-härtbaren zusammensetzungen
SU1424634A1 (ru) Способ радиационной обработки транзисторов
RU95101096A (ru) Способ лечения хронических простатитов
RU96103517A (ru) Способ определения индивидуальной дозовой нагрузки при надсосудистом лазерном облучении крови
RU96120233A (ru) Способ лечения переднего отдела глаза
SU1187831A1 (ru) Способ лечени желтухи новорожденных
KIM et al. Photodynamic therapy for early tongue cancer
PT1007498E (pt) Processo para o fabrico de 2-halogenoindano-1-onas
RU95110907A (ru) Способ лечения онкологических больных
RU2000116758A (ru) Способ контроля дефектности пленок кремния на диэлектрических подложках
RU98113166A (ru) Способ подавления роста раковой опухоли
RU2002130168A (ru) Способ лечения хронических тонзиллитов